display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
atezolizumab plus FOLFOXIRI plus bevacizumab AtezoTRIBE

Study type: